Dermatology News

Sanofi and Regeneron’s drug Dupixent led to clearer skin in most patients in phase 3 trial involving 12- to 17-year-olds with moderate-to-severe atopic dermatitis, according to a press release from the company.

The skin of children with early-onset atopic dermatitis exhibits significantly different phenotypes when compared with the skin of adults with a long-standing history with the disease, according to research published in The Journal of Allergy and Clinical Immunology.

Patients with a rare chronic skin condition called hidradenitis suppurativa may be at risk for developing Crohn’s disease, according to new research published in JAMA Dermatology.

The FDA approved a label update for Taltz 80 mg/mL injection to contain data on psoriasis involving the genital area, according to a press release from Eli Lilly, the product’s manufacturer.

DESTIN, Fla. — Although the incidence of rheumatologic adverse effects associated with immune checkpoint inhibitors is expected to grow with their increased use, these effects remain poorly studied in random clinical trials, according to findings presented at the 2018 Congress of Clinical Rheumatology.

Patients with spondyloarthritis — particularly men with axial disease — had high rates of drug retention of the first TNF inhibitor over 5- and 10-year time periods, according to findings published in the Journal of Rheumatology.

Apremilast monotherapy improved the signs and symptoms of psoriatic arthritis and was well tolerated among patients with no prior treatment with disease-modifying antirheumatic drugs, according to findings published in Rheumatology.

Almost three-quarters of health care providers have adopted some form of telemedicine solutions or services as of 2017, according to data from HIMSS Analytics, with the adoption of services increasing 9% since 2016.

BOSTON — Clinical studies indicate that all JAK inhibitors approved so far are effective across a range of immune-mediated inflammatory disorders, with early onset of benefit reported within 1 to 2 weeks, and maximal benefit at 3 months, according to findings presented here.

BOSTON — Rheumatologists need to be more aware of the nonplaque aspects and symptoms of psoriasis, in order to better screen and diagnose their patients, according to a presentation at the 2018 Interdisciplinary Autoimmune Summit.